Technical Analysis for VERV - Verve Therapeutics, Inc.

Grade Last Price % Change Price Change
D 36.21 1.32% 0.47
VERV closed up 11.13 percent on Tuesday, December 7, 2021, on 1.63 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up
Historical VERV trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.32%
Oversold Stochastic Weakness 1.32%
Wide Bands Range Expansion 12.59%
Oversold Stochastic Weakness 12.59%
Multiple of Ten Bullish Other 13.37%
Wide Bands Range Expansion 13.37%
Down 3 Days in a Row Weakness 13.37%
Oversold Stochastic Weakness 13.37%
Doji - Bullish? Reversal 9.93%
Wide Bands Range Expansion 9.93%
Older End-of-Day Signals for VERV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 36 minutes ago
Up 2% 36 minutes ago
Rose Above Previous Day's High about 1 hour ago
1.5x Volume Pace about 1 hour ago
Down 3% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Verve Therapeutics, Inc. Description

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease


Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Cholesterol Hypercholesterolemia Lipids Low Density Lipoprotein Chronic Management Pcsk9

Is VERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 77.99
52 Week Low 29.5
Average Volume 308,412
200-Day Moving Average 0.00
50-Day Moving Average 44.16
20-Day Moving Average 39.34
10-Day Moving Average 33.74
Average True Range 3.40
ADX 38.31
+DI 12.48
-DI 26.21
Chandelier Exit (Long, 3 ATRs) 45.67
Chandelier Exit (Short, 3 ATRs) 40.07
Upper Bollinger Bands 51.95
Lower Bollinger Band 26.73
Percent B (%b) 0.36
BandWidth 64.10
MACD Line -4.04
MACD Signal Line -3.77
MACD Histogram -0.2724
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.86
Resistance 3 (R3) 40.47 38.38 40.00
Resistance 2 (R2) 38.38 37.08 38.57 39.72
Resistance 1 (R1) 37.06 36.27 37.72 37.45 39.43
Pivot Point 34.97 34.97 35.30 35.16 34.97
Support 1 (S1) 33.65 33.67 34.31 34.04 32.05
Support 2 (S2) 31.56 32.86 31.75 31.76
Support 3 (S3) 30.24 31.56 31.48
Support 4 (S4) 30.63